NASDAQ:ASNS Arsanis (ASNS) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.65▼$3.2350-Day Range$3.11▼$3.1152-Week Range$1.15▼$28.69Volume31,653 shsAverage Volume177,768 shsMarket Capitalization$5.53 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Arsanis (NASDAQ:ASNS) StockX4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.Read More Receive ASNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arsanis and its competitors with MarketBeat's FREE daily newsletter. Email Address ASNS Stock News HeadlinesMay 22, 2023 | finance.yahoo.comActelis To Present at the LD Micro Invitational XIIIMay 18, 2023 | investing.comActelis Networks Inc (ASNS)June 5, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 12, 2023 | finance.yahoo.comActelis Networks Reports Fiscal First Quarter 2023May 8, 2023 | finance.yahoo.comActelis Networks Announces Closing of $3.5 Million Private Placement Priced At-the-Market under Nasdaq RulesMay 4, 2023 | finance.yahoo.comWhy Are Actelis Networks Shares Trading Higher TodayMay 4, 2023 | finance.yahoo.comActelis Networks Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq RulesMay 3, 2023 | finance.yahoo.comWhat's Happening With Actelis Networks Stock TodayJune 5, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 3, 2023 | finance.yahoo.comActelis Networks Regains Compliance With Nasdaq Minimum Bid Price RequirementMay 1, 2023 | finance.yahoo.comActelis Networks Showcases New Hybrid Fiber-Copper Solutions Extending Gigabit Speed Connectivity For IoT Applications and 18 Million Multiple Dwelling UnitsApril 21, 2023 | benzinga.comActelis Networks Stock (NASDAQ:ASNS), DividendsApril 19, 2023 | finance.yahoo.comActelis Networks Announces 1-For-10 Reverse Stock Split to Aid Compliance With Nasdaq Listing RequirementsApril 5, 2023 | finance.yahoo.comCity of West Sacramento Modernizes Traffic Management With Actelis’ Hybrid Fiber-Copper SolutionsMarch 29, 2023 | finance.yahoo.comActelis Networks Reports Fiscal Full Year 2022March 22, 2023 | finance.yahoo.comActelis Networks to Report Fiscal Full Year 2022 Financial Results on Wednesday, March 29, 2023, at 4:30 p.m. ETMarch 8, 2023 | finance.yahoo.comActelis Strengthens Global Footprint With Appointment Of New Asia-Pacific Regional Vice PresidentFebruary 21, 2023 | finance.yahoo.comActelis Selected by the City of Eugene for Traffic Modernization ProjectFebruary 18, 2023 | benzinga.comActelis Networks Stock (NASDAQ:ASNS), Quotes and News SummaryJanuary 13, 2023 | finance.yahoo.comActelis to Present at the Sidoti Virtual Conference on January 18th, 2023January 3, 2023 | finance.yahoo.comActelis Selected By Northern Ireland Railways For Safety Critical ProjectDecember 19, 2022 | finance.yahoo.comActelis Extends Cyber-Hardened, Fiber-Grade, Rapid Deployment Networking to On Base Facilities Using Existing InfrastructureDecember 18, 2022 | reuters.comActelis Networks IncNovember 22, 2022 | finance.yahoo.comActelis Networks, Inc. Authorizes up to $1 Million Share Repurchase ProgramNovember 12, 2022 | finance.yahoo.comActelis Networks Reports Third Quarter and First Nine Months of Fiscal 2022November 4, 2022 | finance.yahoo.comActelis Networks to Report Fiscal Third Quarter 2022 Financial Results on Friday, November 11, 2022, at 4:30 p.m. ETOctober 25, 2022 | finance.yahoo.comActelis Selects Norseman Defense Technologies As Its Latest US Government Focused Sales PartnerSee More Headlines ASNS Company Calendar Last Earnings11/09/2018Today6/04/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Communications equipment, not elsewhere classified Sub-IndustryN/A SectorComputer and Technology Current SymbolNASDAQ:ASNS CUSIPN/A CIK1501697 Webwww.arsanis.com Phone(857) 529-8300FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,980,000.00 Net Margins-93.50% Pretax Margin-93.50% Return on Equity-183.07% Return on Assets-52.55% Debt Debt-to-Equity Ratio2.62 Current Ratio1.03 Quick Ratio0.83 Sales & Book Value Annual Sales$8.83 million Price / Sales0.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book3.90Miscellaneous Outstanding Shares1,940,000Free Float1,642,000Market Cap$5.53 million OptionableNot Optionable BetaN/A Key ExecutivesPaula S. RaganPresident, Chief Executive Officer & DirectorAdam S. MostafaChief Financial Officer & TreasurerCeleste DiJohnsonVice President-Clinical OperationsMary DiBiaseVice President-Technical Operations & QualityTarek EbrahimVice President-Medical Affairs & Rare DiseaseKey CompetitorsCOMSovereignNASDAQ:COMSVislink TechnologiesNASDAQ:VISLQutoutiaoNASDAQ:QTTWiSA TechnologiesNASDAQ:WISASenmiao TechnologyNASDAQ:AIHSView All CompetitorsInsidersTuvia BarlevSold 2,107 sharesTotal: $6,995.24 ($3.32/share)Israel NivSold 422 sharesTotal: $1,401.04 ($3.32/share)View All Insider Transactions ASNS Stock - Frequently Asked Questions Are investors shorting Arsanis? Arsanis saw a increase in short interest in May. As of May 15th, there was short interest totaling 52,800 shares, an increase of 214.3% from the April 30th total of 16,800 shares. Based on an average daily trading volume, of 241,300 shares, the days-to-cover ratio is presently 0.2 days. Currently, 4.0% of the company's shares are short sold. View Arsanis' Short Interest. When is Arsanis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our ASNS earnings forecast. How were Arsanis' earnings last quarter? Arsanis, Inc. (NASDAQ:ASNS) released its earnings results on Friday, November, 9th. The company reported ($7.60) EPS for the quarter, missing analysts' consensus estimates of ($7.40) by $0.20. Arsanis had a negative net margin of 93.50% and a negative trailing twelve-month return on equity of 183.07%. When did Arsanis' stock split? Arsanis shares reverse split on the morning of Wednesday, April 19th 2023. The 1-10 reverse split was announced on Wednesday, April 19th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Arsanis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arsanis investors own include Catalyst Pharmaceuticals (CPRX), NxStage Medical (NXTM), Selecta Biosciences (SELB), CDTi Advanced Materials (CDTI), Curis (CRIS), bluebird bio (BLUE), Juno Therapeutics (JUNO), Nektar Therapeutics (NKTR), Protalix BioTherapeutics (PLX) and Tocagen (TOCA). When did Arsanis IPO? (ASNS) raised $15 million in an initial public offering on Friday, May 13th 2022. The company issued 3,000,000 shares at $4.00-$6.00 per share. Boustead Securities acted as the underwriter for the IPO. What is Arsanis' stock symbol? Arsanis trades on the NASDAQ under the ticker symbol "ASNS." What is Arsanis' stock price today? One share of ASNS stock can currently be purchased for approximately $2.85. How much money does Arsanis make? Arsanis (NASDAQ:ASNS) has a market capitalization of $5.53 million and generates $8.83 million in revenue each year. The company earns $-10,980,000.00 in net income (profit) each year or ($4.79) on an earnings per share basis. How can I contact Arsanis? Arsanis' mailing address is 890 WINTER STREET SUITE 230, WALTHAM MA, 02451. The official website for the company is www.arsanis.com. The company can be reached via phone at (857) 529-8300 or via email at ir@arsanis.com. This page (NASDAQ:ASNS) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arsanis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.